منابع مشابه
Biodefense Countermeasure Development
BIODEFENSE PLANNING BY THE U.S. government emphasizes the use of medical countermeasures, including drugs and vaccines, to prepare for and respond to attacks involving biological weapons.1–4 Currently, medical countermeasures are available for only a fraction of biological threats, including those representing the highest risk, as determined by the Department of Homeland Security’s (DHS) threat...
متن کاملZika Virus: Medical Countermeasure Development Challenges.
INTRODUCTION Reports of high rates of primary microcephaly and Guillain-Barré syndrome associated with Zika virus infection in French Polynesia and Brazil have raised concerns that the virus circulating in these regions is a rapidly developing neuropathic, teratogenic, emerging infectious public health threat. There are no licensed medical countermeasures (vaccines, therapies or preventive drug...
متن کاملMeeting the challenges of medical countermeasure development
Despite substantial investments since the events of 2001, much work remains to prepare the nation for a chemical, biological, radiological or nuclear (CBRN) attack or to respond to an emerging infectious disease threat. Following a 2010 review of the US Public Health Emergency Medical Countermeasures Enterprise, FDA launched its Medical Countermeasures initiative (MCMi) to facilitate the develo...
متن کاملAntimalaria Drug Development & Pipeline
Artemisin traditionally cleave the peroxide bond by Fe(II) found in heme proteins, thus generating toxic oxygen radicals. Synthetic peroxides, thus are proving to be useful substitutes for artemisinin. The first-generation ozonide OZ277, known as arterolane [1], has been found to inhibit the growth of chloroquine-resistant (K1) and chloroquine sensitive (NF54) parasite strains. In 2012, the com...
متن کاملAlzheimer's drug-development pipeline: 2016
BACKGROUND Alzheimer's disease (AD) is growing in frequency and new therapies are urgently needed. METHODS We assessed clinicaltrials.gov (accessed 1-4-2016) to determine the number and characteristics of trials in phase I, phase II, and phase III for treatment of AD. RESULTS There are currently 24 agents in 36 trials in phase III of AD drug development. Seven of these 24 agents are symptom...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Annals of the New York Academy of Sciences
سال: 2016
ISSN: 0077-8923
DOI: 10.1111/nyas.13224